生脉饮协同2H_3R_3Z_3S_3E_3/6H_3R_3E_3治疗方案治疗复治涂阳肺结核的临床研究  

Clinical research on Shengmai Yin plus 2H_3R_3Z_3S_3E_3/6H_3R_3E_3 solution for treating retreatment smear-positive pulmonary tuberculosis

作　　者：敬大成 欧阳海平[1] 白敏[1] 胥展志 万雪梅[1] 

机构地区：[1]成都中医药大学,四川成都610000

出　　处：《中医临床研究》2016年第4期9-11,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:评价生脉饮协同化疗药物治疗复治涂阳肺结核患者的有效性、安全性。方法:选择2012年11月1日-2014年10月1日在我院住院的复治涂阳肺结核患者60例,按照随机分组、单盲临床试验,分为试验组30例,对照组30例。试验组抗肺结核治疗方案为2H3R3Z3S3E3/6H3R3E3+生脉饮,对照组抗肺结核治疗方案为2H3R3Z3S3E3/6H3R3E3+生理盐水。周期设定为32周,强化期为8周,巩固期为24周。结果:痰菌转阴率、病灶及空洞改变情况、免疫功能(T淋巴细胞亚群)方面,试验组明显优于对照组,差异有统计学意义。结论:生脉饮协同化疗药物治疗复治涂阳肺结核患者能提高化疗药物的疗效。Objective： To assess clinical effects and safety of Shengmai Yin plus chemotherapeutics on patients with recurrent-smear positive pulmonary tuberculosis. Methods： 60 patients in our hospital from November 1, 2012 to October 1, 2014 were selected as the study objectives in this paper and divided into the experiment group（30 cases） and the control group（30 cases） according to randomized block and single-blind clinical experiment. The anti-TB therapeutic schedule for the experimental group is 2H3R3Z3S3E3/6H3R3E3 plus Shengmai Yin, while the anti-TB therapeutic schedule for the control group is 2H3R3Z3S3E3/6H3R3E3 plus normal saline. Period is set to 32 weeks, 8 weeks for the intensive phase and 24 weeks for consolidation. Results： The sputum negative conversion rate, changed situation of the lesion and cavity, immune function（T cells subgroup） in the experimental group were much better, and the difference between groups had statistical significance. Conclusion： Shengmai Yin in the treatment of patients with recurrent smear-positive pulmonary tuberculosis can improve the curative effect of chemotherapeutics.

关 键 词：生脉饮 复治 涂阳肺结核 

分 类 号：R521[医药卫生—内科学]